15 November 2022
Latham & Watkins Advises Opiant Pharmaceuticals in Sale to Indivior PLC
Advising firms
Deal team
31 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Christopher Drewry Lead | Latham & Watkins LLP | Partner | corporate | Chicago |
| Max Schleusener Lead | Latham & Watkins LLP | Partner | corporate | Chicago |
| Aidan Milstead | Latham & Watkins LLP | Associate | corporate | Not stated |
| Joshua Reisman | Latham & Watkins LLP | Associate | corporate | Not stated |
| Byron Patton | Latham & Watkins LLP | Associate | corporate | Not stated |
| Jesse Lake | Latham & Watkins LLP | Associate | corporate | Not stated |
| Cyerra McGowan | Latham & Watkins LLP | Associate | corporate | Not stated |
| Alex Storozum | Latham & Watkins LLP | Associate | corporate | Not stated |
| John Manthei | Latham & Watkins LLP | Partner | FDA regulatory | Washington D.C. |
| Betty Pang | Latham & Watkins LLP | Counsel | FDA regulatory | Bay Area |
| Nathan Beaton | Latham & Watkins LLP | Associate | FDA regulatory | Not stated |
| Meryl Bartlett | Latham & Watkins LLP | Associate | FDA regulatory | Not stated |
| Gabriel Gross | Latham & Watkins LLP | Partner | intellectual property | Bay Area |
| Steven Chinowsky | Latham & Watkins LLP | Partner | intellectual property | San Diego |
| Darryl Steensma | Latham & Watkins LLP | Counsel | intellectual property | San Diego |
| Kathryn Parsons-Reponte | Latham & Watkins LLP | Associate | intellectual property | Not stated |
| Kristina Funahashi | Latham & Watkins LLP | Associate | intellectual property | Not stated |
| Michelle Carpenter | Latham & Watkins LLP | Partner | benefits and compensation | Los Angeles |
| Laura Szarmach | Latham & Watkins LLP | Counsel | benefits and compensation | Washington D.C. |
| Joe Benedetto | Latham & Watkins LLP | Associate | benefits and compensation | Not stated |
| Scott Ollivierre | Latham & Watkins LLP | Partner | finance | New York |
| Ricky Burks | Latham & Watkins LLP | Associate | finance | Not stated |
| Scott Westhoff | Latham & Watkins LLP | Partner | capital markets and securities | Chicago |
| David Schindler | Latham & Watkins LLP | Partner | litigation | Los Angeles |
| Colleen Smith | Latham & Watkins LLP | Partner | litigation | San Diego |
| Pardis Zomorodi | Latham & Watkins LLP | Partner | tax | Los Angeles |
| Jeffrey Anderson | Latham & Watkins LLP | Counsel | real estate | Chicago |
| Heather Deixler | Latham & Watkins LLP | Partner | data privacy | Bay Area |
| Jim Barker | Latham & Watkins LLP | Partner | CFIUS | Washington D.C. |
| Joshua Holian | Latham & Watkins LLP | Partner | antitrust | Bay Area |
| Matthew Piehl | Latham & Watkins LLP | Associate | antitrust | Not stated |
28 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 20 (US$20 per share)
- What the figure measures
- Per share
- Client
- Opiant Pharmaceuticals Inc.Sell-side
- Counterparties
- Indivior Inc (Buy-side)